Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Stocks · News reference
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate
Dr. Reddy's Expands Collaboration With Gilead Sciences Through Voluntary Licensing Agreement For Investigational Once-Yearly Lenacapavir For HIV Prevention
Gilead Sciences Announces Expansion Of Six Royalty-Free Voluntary Licensing Agreements To Cover Once-Yearly Lenacapavir For HIV Prevention Across 120 Countries
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access
The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.